{"id":32751,"date":"2014-10-03T10:03:56","date_gmt":"2014-10-03T14:03:56","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=32751"},"modified":"2014-10-03T10:03:56","modified_gmt":"2014-10-03T14:03:56","slug":"amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751","title":{"rendered":"Amgen, Inc. (NASDAQ:AMGN) Says Lancet Publishes Two Stage Three Trials Indicating Cholesterol-Lowering Medication Evolocumab"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 10\/03\/2014 (wallstreetpr) \u2013 <strong>Amgen, Inc. (NASDAQ:AMGN)<\/strong> disclosed that the Lancet published data from two Stage three trials, TESLA and RUTHERFORD-2. The data pointed out that the treatment with novel investigational low-density lipoprotein cholesterol or LDL-C, evolocumab, resulted in a statistically important reduction in LDL-C. The data compared with the placebo in patients affected by various kinds of familial hypercholesterolemia.<\/p>\n<p style=\"text-align: justify;\"><strong>Inherited Condition<\/strong><\/p>\n<p style=\"text-align: justify;\">The Amgen, Inc. (NASDAQ:AMGN) said that Familial hypercholesterolemia was an inherited condition originated from a gene mutation that led to increased levels of LDL-C, which was also known as bad cholesterol, its <a href=\"http:\/\/finance.yahoo.com\/news\/lancet-publishes-two-phase-3-230100399.html\" target=\"_blank\">statement<\/a> revealed. This has the potential of a premature cardiovascular disease.<\/p>\n<p style=\"text-align: justify;\">Amgen, Inc. (NASDAQ:AMGN) said that Evolocumab was an investigational completely human monoclonal antibody, which restrains proprotein convertase kexin\/subtilisin type 9, a type of protein that cuts the capability of the liver to eliminate LDL-C from the blood.<\/p>\n<p style=\"text-align: justify;\"><strong>Most Common Form<\/strong><\/p>\n<p style=\"text-align: justify;\">The company said that high cholesterol, especially elevated LDL-C, was the most family type of dyslipidemia. This was known as abnormality of fats or cholesterol in the blood. It pointed out that elevated LDL-C was considered as a big risk element for cardiovascular disease.<\/p>\n<p style=\"text-align: justify;\"><strong>Management Comments<\/strong><\/p>\n<p style=\"text-align: justify;\">Amgen, Inc. (NASDAQ:AMGN)\u2019s Executive VP of R&amp;D, Sean Harper, said that the results from the two stage three trials supported the efficacy of evolocumab as a therapy option for the patients of both the types of familial hypercholesterolemia. The familial hypercholesterolemia was known for struggling to manage their cholesterol levels.<\/p>\n<p style=\"text-align: justify;\">He said that it has filed submissions for evolocumab in the U.S., as well as, European Union, based on a number of other trials in its clinical study program apart from the data reported recently.<\/p>\n<p style=\"text-align: justify;\">South Africa\u2019s Witwatersrand University Lead investigator, Frederick Raal, said that results of TESLA and RUTHERFORD-2 clinical trials indicated the possibility of Evolocumab offering to deliver reduced level of LDL cholesterol. Interestingly, RUTHERFORD-2 trial evaluated 329 patients of heterozygous FH.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 10\/03\/2014 (wallstreetpr) \u2013 Amgen, Inc. (NASDAQ:AMGN) disclosed that the Lancet published data from two Stage three trials, TESLA and RUTHERFORD-2. The data pointed [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":23206,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[7095,2831,10100,1520,10099],"stock_ticker":[],"class_list":["post-32751","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-amgen-inc","tag-amgen-inc-nasdaqamgn","tag-frederick-raal","tag-nasdaqamgn","tag-sean-harper","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Amgen, Inc. (NASDAQ:AMGN) Says Lancet Publishes Two Stage Three Trials Indicating Cholesterol-Lowering Medication Evolocumab - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen, Inc. (NASDAQ:AMGN) Says Lancet Publishes Two Stage Three Trials Indicating Cholesterol-Lowering Medication Evolocumab - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 10\/03\/2014 (wallstreetpr) \u2013 Amgen, Inc. (NASDAQ:AMGN) disclosed that the Lancet published data from two Stage three trials, TESLA and RUTHERFORD-2. The data pointed [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-03T14:03:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/amgen-inc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"413\" \/>\n\t<meta property=\"og:image:height\" content=\"122\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fiona Gibson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fiona Gibson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751\"},\"author\":{\"name\":\"Fiona Gibson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e\"},\"headline\":\"Amgen, Inc. (NASDAQ:AMGN) Says Lancet Publishes Two Stage Three Trials Indicating Cholesterol-Lowering Medication Evolocumab\",\"datePublished\":\"2014-10-03T14:03:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751\"},\"wordCount\":337,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/amgen-inc.jpg\",\"keywords\":[\"Amgen Inc.\",\"Amgen Inc. (NASDAQ:AMGN)\",\"Frederick Raal\",\"NASDAQ:AMGN\",\"Sean Harper\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751\",\"name\":\"Amgen, Inc. (NASDAQ:AMGN) Says Lancet Publishes Two Stage Three Trials Indicating Cholesterol-Lowering Medication Evolocumab - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/amgen-inc.jpg\",\"datePublished\":\"2014-10-03T14:03:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/amgen-inc.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/amgen-inc.jpg\",\"width\":413,\"height\":122},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amgen, Inc. (NASDAQ:AMGN) Says Lancet Publishes Two Stage Three Trials Indicating Cholesterol-Lowering Medication Evolocumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e\",\"name\":\"Fiona Gibson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg\",\"caption\":\"Fiona Gibson\"},\"description\":\"Fiona is a finance graduate and an expert in analyzing market trends.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\",\"https:\/\/x.com\/@fionahime\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/fiona-gibson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amgen, Inc. (NASDAQ:AMGN) Says Lancet Publishes Two Stage Three Trials Indicating Cholesterol-Lowering Medication Evolocumab - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751","og_locale":"en_US","og_type":"article","og_title":"Amgen, Inc. (NASDAQ:AMGN) Says Lancet Publishes Two Stage Three Trials Indicating Cholesterol-Lowering Medication Evolocumab - Wall Street PR","og_description":"Boston, MA 10\/03\/2014 (wallstreetpr) \u2013 Amgen, Inc. (NASDAQ:AMGN) disclosed that the Lancet published data from two Stage three trials, TESLA and RUTHERFORD-2. The data pointed [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-10-03T14:03:56+00:00","og_image":[{"width":413,"height":122,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/amgen-inc.jpg","type":"image\/jpeg"}],"author":"Fiona Gibson","twitter_misc":{"Written by":"Fiona Gibson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751"},"author":{"name":"Fiona Gibson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e"},"headline":"Amgen, Inc. (NASDAQ:AMGN) Says Lancet Publishes Two Stage Three Trials Indicating Cholesterol-Lowering Medication Evolocumab","datePublished":"2014-10-03T14:03:56+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751"},"wordCount":337,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/amgen-inc.jpg","keywords":["Amgen Inc.","Amgen Inc. (NASDAQ:AMGN)","Frederick Raal","NASDAQ:AMGN","Sean Harper"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751","url":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751","name":"Amgen, Inc. (NASDAQ:AMGN) Says Lancet Publishes Two Stage Three Trials Indicating Cholesterol-Lowering Medication Evolocumab - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/amgen-inc.jpg","datePublished":"2014-10-03T14:03:56+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/amgen-inc.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/amgen-inc.jpg","width":413,"height":122},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-says-lancet-publishes-two-stage-three-trials-indicating-cholesterol-lowering-medication-evolocumab-32751#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Amgen, Inc. (NASDAQ:AMGN) Says Lancet Publishes Two Stage Three Trials Indicating Cholesterol-Lowering Medication Evolocumab"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e","name":"Fiona Gibson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg","caption":"Fiona Gibson"},"description":"Fiona is a finance graduate and an expert in analyzing market trends.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr","https:\/\/x.com\/@fionahime"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/fiona-gibson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=32751"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32751\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/23206"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=32751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=32751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=32751"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=32751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}